HRP20041048B1 - POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINE - Google Patents
POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINEInfo
- Publication number
- HRP20041048B1 HRP20041048B1 HRP20041048AA HRP20041048A HRP20041048B1 HR P20041048 B1 HRP20041048 B1 HR P20041048B1 HR P20041048A A HRP20041048A A HR P20041048AA HR P20041048 A HRP20041048 A HR P20041048A HR P20041048 B1 HRP20041048 B1 HR P20041048B1
- Authority
- HR
- Croatia
- Prior art keywords
- polymorph
- ethoxyethyl
- piperidinyl
- dimethyl
- ethyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- -1 2-ethoxyethyl Chemical group 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000037273 Pathologic Processes Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009054 pathological process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Opisan je polimorf 1 4-[2-[4-[1-(2-etoksietil)-1H-benzimidazol-2-il]-1-piperidinil]etil]- α, α-dimetil-benzenoctene kiseline s formulom (I), procedure za njegovu pripravu, farmaceutske formule koje sadržavaju polimorf 1 i upotreba polimorfa 1 za tretiranje alergijskih reakcija i patoloških procesa posredovanih histaminom kod sisavaca kakav je čovjek.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2002/000194 WO2003089425A1 (es) | 2002-04-19 | 2002-04-19 | POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO |
Publications (3)
Publication Number | Publication Date |
---|---|
HRP20041048A2 HRP20041048A2 (en) | 2005-02-28 |
HRP20041048A9 HRP20041048A9 (hr) | 2013-01-31 |
HRP20041048B1 true HRP20041048B1 (hr) | 2013-04-30 |
Family
ID=29225789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20041048AA HRP20041048B1 (hr) | 2002-04-19 | 2004-11-09 | POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINE |
Country Status (31)
Country | Link |
---|---|
US (2) | US7612095B2 (hr) |
EP (1) | EP1505066B1 (hr) |
JP (1) | JP5142448B2 (hr) |
KR (1) | KR100673140B1 (hr) |
CN (1) | CN1290843C (hr) |
AR (1) | AR039423A1 (hr) |
AT (1) | ATE347550T1 (hr) |
AU (1) | AU2002255017B2 (hr) |
BG (1) | BG66302B1 (hr) |
BR (1) | BRPI0215703B8 (hr) |
CA (1) | CA2484460C (hr) |
CY (2) | CY1107564T1 (hr) |
CZ (1) | CZ305162B6 (hr) |
DE (1) | DE60216641T2 (hr) |
DK (1) | DK1505066T3 (hr) |
ES (1) | ES2278018T3 (hr) |
HK (1) | HK1072772A1 (hr) |
HR (1) | HRP20041048B1 (hr) |
HU (1) | HU230032B1 (hr) |
IL (1) | IL164645A (hr) |
MX (1) | MXPA04010313A (hr) |
NO (1) | NO329327B1 (hr) |
NZ (1) | NZ536551A (hr) |
PA (1) | PA8571201A1 (hr) |
PE (1) | PE20040086A1 (hr) |
PT (1) | PT1505066E (hr) |
SI (1) | SI1505066T1 (hr) |
SK (1) | SK288052B6 (hr) |
UA (1) | UA76866C2 (hr) |
UY (1) | UY27762A1 (hr) |
WO (1) | WO2003089425A1 (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010013472A (ja) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | 4−[2−[1−(2−エトキシエチル)−1H−ベンズイミダゾール−2−イル]−1−ピペリジニル]エチル]−α,α−ジメチルベンゼノ酢酸の多形体 |
JP6023054B2 (ja) * | 2011-06-30 | 2016-11-09 | パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカPanasonic Intellectual Property Corporation of America | 通信システム、ユーザ端末並びに通信装置 |
CN102675101B (zh) * | 2012-05-16 | 2014-01-29 | 王蕾 | 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法 |
CZ307500B6 (cs) | 2012-08-15 | 2018-10-24 | Zentiva, K.S. | Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty |
CN103214454A (zh) * | 2013-03-30 | 2013-07-24 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀晶型及制备方法 |
WO2014188453A2 (en) * | 2013-05-24 | 2014-11-27 | Msn Laboratories Private Limited | Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid |
CN103356616A (zh) * | 2013-06-29 | 2013-10-23 | 北京万全德众医药生物技术有限公司 | 一种含有比拉斯汀的药物组合物及其制备方法 |
CN104447682A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 比拉斯汀化合物 |
CN104398481A (zh) * | 2014-10-29 | 2015-03-11 | 万全万特制药江苏有限公司 | 比拉斯汀口崩片及其制备方法 |
JP7168447B2 (ja) * | 2015-07-24 | 2022-11-09 | ウルキマ,ソシエダッド アノニマ | ビラスチンの結晶形態及びそれらの調製方法 |
EP3170817A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Co-crystals of benzimidazole compounds |
EP3170816A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Supersaturated compositions of benzimidazole compounds |
WO2017167949A1 (en) | 2016-04-01 | 2017-10-05 | Krka, D.D., Novo Mesto | Crystalline forms of bilastine |
EP3452462A4 (en) * | 2016-05-05 | 2019-10-23 | MSN Laboratories Private Limited, R&D Center | SOLID STATE FORMS OF 2- [4- (2- {4- [1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOL-2-YL] -1-PIPERIDINYL} ETHYL) PHENYL] -2-METHYLPROPANOIC ACID AND PREPARATION METHOD THEREOF |
ES2813561T3 (es) | 2017-09-07 | 2021-03-24 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica en comprimido que comprende bilastina |
ES2835287T3 (es) | 2017-12-18 | 2021-06-22 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio |
PL3641735T3 (pl) | 2017-12-18 | 2021-09-06 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Kompozycja farmaceutyczna tabletki zawierająca bilastynę w postaci 3 i rozpuszczalny w wodzie wypełniacz |
PT3740191T (pt) | 2018-01-18 | 2021-07-09 | Faes Farma Sa | Composições oftálmicas compreendendo bilastina, uma beta-ciclodextrina e pelo menos um agente gelificante |
WO2022135863A1 (en) | 2020-12-23 | 2022-06-30 | Biohorm, S.L. | A non-micronized bilastine composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0818454A1 (en) * | 1996-06-04 | 1998-01-14 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) | Benzimidazole derivatives with antihistaminic activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4810789A (en) * | 1987-08-28 | 1989-03-07 | Bristol-Myers Company | Process for buspirone hydrochloride polymorphic crystalline form conversion |
EP1171430A1 (en) * | 1999-04-16 | 2002-01-16 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them |
AP1598A (en) * | 1999-04-23 | 2006-04-26 | Smithkline Beecham Plc | Polymorph of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt. |
-
2002
- 2002-04-19 BR BRPI0215703A patent/BRPI0215703B8/pt active IP Right Grant
- 2002-04-19 ES ES02724323T patent/ES2278018T3/es not_active Expired - Lifetime
- 2002-04-19 JP JP2003586146A patent/JP5142448B2/ja not_active Expired - Lifetime
- 2002-04-19 DK DK02724323T patent/DK1505066T3/da active
- 2002-04-19 CA CA002484460A patent/CA2484460C/en not_active Expired - Fee Related
- 2002-04-19 HU HU0500241A patent/HU230032B1/hu unknown
- 2002-04-19 US US10/511,822 patent/US7612095B2/en not_active Expired - Lifetime
- 2002-04-19 DE DE60216641T patent/DE60216641T2/de not_active Expired - Lifetime
- 2002-04-19 EP EP02724323A patent/EP1505066B1/en not_active Expired - Lifetime
- 2002-04-19 SI SI200230485T patent/SI1505066T1/sl unknown
- 2002-04-19 KR KR1020047016676A patent/KR100673140B1/ko active IP Right Grant
- 2002-04-19 WO PCT/ES2002/000194 patent/WO2003089425A1/es active IP Right Grant
- 2002-04-19 MX MXPA04010313A patent/MXPA04010313A/es active IP Right Grant
- 2002-04-19 CZ CZ2004-1122A patent/CZ305162B6/cs not_active IP Right Cessation
- 2002-04-19 CN CNB028289870A patent/CN1290843C/zh not_active Ceased
- 2002-04-19 AT AT02724323T patent/ATE347550T1/de active
- 2002-04-19 UA UA20041109444A patent/UA76866C2/uk unknown
- 2002-04-19 PT PT02724323T patent/PT1505066E/pt unknown
- 2002-04-19 SK SK5020-2004A patent/SK288052B6/sk not_active IP Right Cessation
- 2002-04-19 AU AU2002255017A patent/AU2002255017B2/en not_active Expired
- 2002-04-19 NZ NZ536551A patent/NZ536551A/en not_active IP Right Cessation
-
2003
- 2003-04-14 PE PE2003000376A patent/PE20040086A1/es active IP Right Grant
- 2003-04-14 UY UY27762A patent/UY27762A1/es not_active Application Discontinuation
- 2003-04-15 AR ARP030101325A patent/AR039423A1/es not_active Application Discontinuation
- 2003-04-16 PA PA20038571201A patent/PA8571201A1/es unknown
-
2004
- 2004-10-17 IL IL164645A patent/IL164645A/en active IP Right Grant
- 2004-11-09 HR HRP20041048AA patent/HRP20041048B1/hr not_active IP Right Cessation
- 2004-11-17 NO NO20044999A patent/NO329327B1/no not_active IP Right Cessation
- 2004-11-18 BG BG108941A patent/BG66302B1/bg unknown
-
2005
- 2005-07-27 HK HK05106418A patent/HK1072772A1/xx not_active IP Right Cessation
-
2007
- 2007-02-23 CY CY20071100259T patent/CY1107564T1/el unknown
-
2009
- 2009-09-16 US US12/561,148 patent/US20100004285A1/en not_active Abandoned
-
2013
- 2013-04-24 CY CY2013015C patent/CY2013015I1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0818454A1 (en) * | 1996-06-04 | 1998-01-14 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) | Benzimidazole derivatives with antihistaminic activity |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20041048B1 (hr) | POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINE | |
NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
BR0313176A (pt) | Composições de pirazol úteis como inibidores de gsk-3 | |
ATE400573T1 (de) | 1h-imidazochinolinderivate als proteinkinaseinhibitoren | |
EP2269610A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
MA31090B1 (fr) | Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase | |
EP2266569A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
NO20055129L (no) | Fenylsubstituerte karboksylsyrer | |
WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
NO20090328L (no) | Nye forbindelser 385 | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
MA30063B1 (fr) | Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fcg) | |
NO20090327L (no) | Nye forbindelser 384 | |
MY136761A (en) | Oxazol derivatives | |
NO20053742L (no) | Tri (cyclo)-substituerte amidforbindelser | |
NO20092033L (no) | Nye forbindelser | |
WO2007046867A3 (en) | Piperidine derivatives and their uses as therapeutic agents | |
WO2006085113A3 (en) | 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists | |
EP1689713A4 (en) | BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | |
ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
A9IS | Complete republication of an hr-a document | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190405 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200406 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210402 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20220419 |